Skip to main content

Table 1 Patient and clinical characteristics

From: Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

Characteristics

I-SPY 1 TRIAL evaluable patients (n = 221)

Matched T1-T2 pairs (n = 36)

P-value

Matched T1-TS pairs (n = 39)

P-value

Age, yr

  

0.77a

 

0.86a

 Median (range)

49 (26–28)

47 (31–68)

48 (34–65)

Clinical tumor size, cm

     

 Median (range)

6 (0–25)c

6 (3–17)

0.55a

6 (0–25)c

0.88a

 Clinically node-positive at diagnosis

143 (65 %)

25 (69 %)

 

26 (67 %)

 

 Histological grade (baseline)

     

 Low

18 (8 %)

1 (3 %)

0.39b

4 (10 %)

0.83b

 Intermediate

96 (43 %)

20 (56 %)

17 (44 %)

 High

103 (47 %)

15 (42 %)

18 (46 %)

 Indeterminate

4 (2 %)

0

0

Clinical stage (baseline)

     

 I

3 (1 %)

0

0.80b

0

0.66b

 II

104 (47 %)

15 (42 %)

 

 III

96 (43 %)

18 (50 %)

16 (41 %)

 Inflammatory

17 (8 %)

3 (8 %)

5 (13 %)

 Indeterminate

1 (<1 %)

0

0

 Hormone receptor-positive (ER or PR) at baseline

131 (59 %)

24 (67 %)

0.55b

26 (68 %)

0.41b

 HER2-positive at baseline

67 (31 %)

6 (17 %)

0.12b

3 (8 %)

0.006b

Neoadjuvant treatment

     

 AC only

11 (5 %)

3 8 %)

0.21b

2 (5 %)

0.38b

 AC + taxane

187 (85 %)

33 (92 %)

33 (85 %)

 AC + T + Trastuzumab

20 (9 %)

0

2 (5 %)

AC + T + Other

3 (1 %)

0

2 (5 %)

Surgery type

 Mastectomy

123 (56 %)

19 (53 %)

0.95b

22 (56 %)

0.58b

 Lumpectomy

92 (41 %)

16 (44 %)

17 (44 %)

 No surgery

6 (3 %)

1 (3 %)

 

RCB

 0

56 (25 %)

6 (17 %)

0.29b

0

0.0002b

 I

18 (8 %)

1 (3 %)

1 (3 %)

 II

86 (39 %)

16 (44 %)

18 (46 %)

 III

41 (19 %)

10 (28 %)

16 (41 %)

 Undetermined

20 (9 %)

3 (8 %)

4 (10 %)

  1. aWilcoxon rank-sum test. bχ2 test. cOne patient had a tumor that measured 0 cm with calipers by clinical examination but had a >3-cm tumor revealed by magnetic resonance imaging (MRI) and was therefore eligible for the trial. Abbreviations: AC anthracycline, ER estrogen receptor, HER2 Human epidermal growth factor receptor 2, PR progesterone receptor, RCB residual cancer burden